Nataliya Prokhnevska

Oct 14, 2024 | nature.com | Caroline Jansen |Maria Cardenas |Nataliya Prokhnevska |Scott Wilkinson |Aparna H. Kesarwala |Vishal R. Dhere | +3 more

AbstractEnhancing the efficacy of immunotherapy in brain metastases (BrM) requires an improved understanding of the immune composition of BrM and how this is affected by radiation and dexamethasone. Our two-arm pilot study (NCT04895592) allocated 26 patients with BrM to either low (Arm A) or high (Arm B) dose peri-operative dexamethasone followed by pre-operative stereotactic radiosurgery (pSRS) and resection (n= 13 per arm). The primary endpoint, a safety analysis at 4 months, was met.